Cat. No.: HY-189903

NJT-12

NJT-12 is a PARP-1 and CK2α inhibitor with IC₅₀ values of 3.40 nM and 4.31 nM, respectively. NJT-12 blocks DNA single-strand break repair, promotes DNA damage, and interferes with tumor stemness signaling by inhibiting CK2α-mediated substrate phosphorylation. NJT-12 induces apoptosis through caspase signaling and G2-M phase arrest, inhibits migration and invasion, and reverses epithelial-mesenchymal transition. NJT-12 inhibits tumor growth in xenograft models with a favorable biosafety profile. NJT-12 can be used for research on ovarian cancer.

For research use only. We do not sell to patients.

Formula: C₂₀H₁₇N₅O₃S
Molecular Weight:407.45

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

NJT-12 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

PARP-1

3.40 nM (IC₅₀)

CK2α

4.31 nM (IC₅₀)

All PARP Isoforms :

All Casein Kinase Isoforms :

All Bcl-2 Family Isoforms :

All Caspase Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
SK-OV-3	IC50	5.43 μM	Cytotoxicity against human SKOV3 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against human SKOV3 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel
A2780	IC50	4.69 μM	Cytotoxicity against human A2780 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against human A2780 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel
MCF7	IC50	9.57 μM	Cytotoxicity against human MCF-7 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against human MCF-7 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel
MDA-MB-231	IC50	8.71 μM	Cytotoxicity against human MDA-MB-231 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against human MDA-MB-231 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel
PC-3	IC50	9.26 μM	Cytotoxicity against human PC-3 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against human PC-3 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel
L02	IC50	59.57 μM	Cytotoxicity against normal human L02 cells assessed as viability reduction after 72 hrs incubation by MTT assay. Cytotoxicity against normal human L02 cells assessed as viability reduction after 72 hrs incubation by MTT assay.	Simultaneous-Inhibition-of-PARP-1-and-CK2-by-Novel

In Vitro

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

NJT-12 (72 h) exhibits broad cytotoxicity against non-HRD cancer cell lines, with the greatest sensitivity observed in A2780 ovarian cancer cells (IC₅₀ 4.69 μM), while showing no significant effect on normal L02 cells^[1].
NJT-12 (5.0-15.0 μM; 12 h) inhibits PARP-1 activity, induces γH2AX, and inhibits CK2α substrate phosphorylation in A2780 cells in a dose-dependent manner^[1].
NJT-12 (2.5-7.5 μM; 24 h) inhibits colony formation of A2780 cells in a concentration-dependent manner^[1].
NJT-12 (2.5-7.5 μM; 24 h) inhibits A2780 cell invasion and migration in a concentration-dependent manner^[1].
NJT-12 (10.0 μM; 24 h) reverses the EMT phenotype of A2780 cells by upregulating E-cadherin and downregulating N-cadherin^[1].
NJT-12 (15.0 μM; 24 h) inhibits the CSC-related transcription factors OCT4, SOX2, and Nanog in A2780 cells more strongly than CX-4945^[1].
NJT-12 (5.0 μM; 10 days) inhibits 3D tumor sphere formation in A2780ALDH1A1+ ovarian cancer stem-like cells^[1].
NJT-12 inhibits ALDH1A1 expression in A2780 cells more strongly than CX-4945^[1].
NJT-12 regulates the Wnt/β-catenin pathway in A2780 cells by increasing DKK1 and decreasing p-GSK-3βSer9 and β-catenin^[1].

Anti-cancer

Apoptosis

NJT-12 (5.0-15.0 μM; 24 h) induces apoptosis in A2780 cells^[1].
NJT-12 (5.0-15.0 μM; 24 h) activates the caspase signaling pathway in A2780 cells by downregulating Bcl-2/pro-caspases and upregulating Bax/cleaved caspases and cleaved-PARP^[1].

Anti-cancer

Cell Cycle Regulation

NJT-12 (5.0-15.0 μM; 24 h) induces G2-M phase cell cycle arrest in A2780 cells in a concentration-dependent manner^[1].

Others

NJT-12 (0.1 nM-2 μM) is a potent dual PARP-1/CK2α inhibitor in cell-free enzyme assays, with IC₅₀ values of 3.40 nM and 4.31 nM for PARP-1 and CK2α, respectively, and exhibits selectivity for PARP-1 over PARP-2^[1].
NJT-12 (1.0 μM; 0-45 min) is metabolically stable in human, rat, and mouse liver microsomes, with T_1/2 values of 51.38 min, 55.58 min, and 26.16 min, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A2780 human ovarian cancer cells
Concentration:

5.0, 10.0, 15.0 μM
Incubation Time:

12 h
Result:

Dose-dependently diminished intracellular PAR polymers; at 15.0 μM, PAR polymer expression was inhibited by over 90%.
γH2AX expression was upregulated with increasing concentration; at 10.0 μM, γH2AX levels were higher than in the Olaparib group.
Also dose-dependently downregulated p-Akt1S129 and p-Cdc37S13, with stronger inhibition than CX-4945 under identical dosing conditions.

Cell Cycle Analysis^[1]

Cell Line:

A2780 human ovarian cancer cells
Concentration:

5.0, 10.0, 15.0 μM
Incubation Time:

24 h
Result:

Downregulated the proportions of cells in G0-G1 and S phases and concentration-dependently elevated the G2-M population.
The control G2-M percentage was 15.30%; after 5.0 μM, G2-M increased to 28.55%; at 15.0 μM, G2-M increased to 38.74%.

Apoptosis Analysis^[1]

Cell Line:

A2780 human ovarian cancer cells
Concentration:

5.0, 10.0, 15.0 μM
Incubation Time:

24 h
Result:

Induced apoptosis in a dose-dependent manner.
At 15.0 μM, the apoptotic ratio was 50.2%; at 10.0 μM, the apoptosis rate was 33.20%.
At 10.0 μM, positive controls CX-4945 and Olaparib induced apoptosis at rates of 22.78% and 29.80%, respectively.

Western Blot Analysis^[1]

Cell Line:

A2780 human ovarian cancer cells
Concentration:

5.0, 10.0, 15.0 μM
Incubation Time:

24 h
Result:

Downregulated Bcl-2, pro-caspase-3, and pro-caspase-9, and upregulated Bax, cleaved-caspase-3, cleaved-caspase-9, and cleaved-PARP in a dose-dependent pattern.
At the same concentration, had stronger modulatory effects than positive control agents.

Western Blot Analysis^[1]

Cell Line:

A2780 human ovarian cancer cells
Concentration:

10.0 μM
Incubation Time:

24 h
Result:

Upregulated E-cadherin and downregulated N-cadherin relative to the control group.
Exerted superior efficacy in reversing the EMT phenotype compared with CX-4945 and Olaparib.

Real Time qPCR^[1]

Cell Line:

A2780 cancer cells
Concentration:

15.0 μM
Incubation Time:

24 h
Result:

Inhibited the transcriptional levels of OCT4, SOX2, and Nanog more strongly than CX-4945, with the most significant inhibition nearly twice or higher than CX-4945.

Cell Invasion Assay^[1]

Cell Line:

A2780 cancer cells
Concentration:

2.5, 5 and 7.5 μM
Incubation Time:

24 h
Result:

Inhibited the invasion and migration of A2780 cells in a concentration-dependent manner; at 7.5 μM, the inhibition rates for invasion and migration were 84.47% and 82.20%, respectively.

Parmacokinetics

Species	Dose	Route	T_max	C_max	T_1/2	AUC_last	AUC_inf	CL	V_ss	MRT	F
Rat^[1]	2.0 mg/kg	i.v.	/	/	4.72 h	6438 ng·h/mL	6482 ng·h/mL	0.341 L/h/kg	0.405 L/kg	1.32 h	44 %
Rat^[1]	10.0 mg/kg	p.o.	0.350 h	5843 ng/mL	3.92 h	15,723 ng·h/mL	15,723 ng·h/mL	/	/	/	/

In Vivo

Anti-cancer

NJT-12 (25.0-100.0 mg/kg; i.g.; once daily; for 21 consecutive days) dose-dependently inhibits the growth of A2780 xenograft tumors in nude mice without causing significant body weight loss^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude (female, 5 weeks old, body weight 16-18 g)^[1]
Dosage:

25.0 mg/kg, 50.0 mg/kg, and 100.0 mg/kg
Administration:

i.g. (intragastric gavage); once daily; 21 consecutive days
Result:

Tumor growth inhibition rate was 43.20% at 25.0 mg/kg, 68.86% at 50.0 mg/kg, and 79.66% at 100.0 mg/kg.
No substantial body weight loss was observed during the whole administration cycle, including in the high-dose group.

Related Protocols :

Chemical Information

Molecular Weight 407.45
Formula C₂₀H₁₇N₅O₃S
SMILES

N/C(SC)=N\N=C\C1=CC=C(C2=NC3=C(OC4=CC(OC)=CC=C43)C(N2)=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Wang Y, et al. Simultaneous Inhibition of PARP-1 and CK2α by Novel Benzothieno [3, 2-d] pyrimidin-4 (1 H)-one Derivatives: A Promising Strategy to Combat Homologous Recombination Deficiency-Independent Tumors and Metastasis[J]. Journal of Medicinal Chemistry, 2026, 69(19): 22283-22304.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NJT-12

All PARP Isoforms

All Casein Kinase Isoforms

All Bcl-2 Family Isoforms

All Caspase Isoforms